Albuminuria News and Research

RSS

Albuminuria also called proteinuria or urine albumin—is a condition in which urine contains an abnormal amount of protein. Albumin is the main protein in the blood. Proteins are the building blocks for all body parts, including muscles, bones, hair, and nails. Proteins in the blood also perform a number of important functions. They protect the body from infection, help blood clot, and keep the right amount of fluid circulating throughout the body.

GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline

The diabetes drugs glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs may also help to slow decline in kidney function in people with type 2 diabetes and albuminuria (high protein levels in the urine), finds a large US study published by The BMJ today.

17 Sep 2026

Severe gum disease linked to early kidney function decline

A growing body of research suggests that the effects of periodontitis extend far beyond the mouth.

2 Jul 2026

Major trials show finerenone preserves kidney function beyond diabetes

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.

5 Jun 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Heart disease risk prediction tool proves effective across global populations

A tool developed by the American Heart Association (AHA), proven to accurately predict heart disease risk for Americans, can be applied to the global population, a new study led by NYU Langone Health shows.

7 May 2026

Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40 %, in adults in the UK.

From Bayer PLC 13 Apr 2026

BNP predicts kidney disease progression risk in diabetes patients

The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, a complex physiological link in which damage to one organ can accelerate deterioration in the other.

24 Mar 2026

Nearly half of adults now live with heart disease as obesity and diabetes surge

The 2026 American Heart Association Heart Disease and Stroke Statistics report shows that nearly half of adults are living with cardiovascular disease, with cardiometabolic risk factors projected to rise substantially by 2050. Despite progress in smoking reduction and cholesterol control, worsening obesity, diabetes, hypertension, sleep health, and persistent inequities threaten future cardiovascular health.

22 Jan 2026

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

New approach to kidney transplant listing could improve outcomes and equity

The current kidney transplant waitlisting criterion is based on a single measurement of kidney function (estimated glomerular filtration rate [eGFR] ≤20 ml/min/1.73m2) and does not consider an individual's risk of progressing to kidney failure.

13 Nov 2025

Expanding the waitlisting criteria for kidney transplantation could improve patient outcomes

The current kidney transplant waitlistingcriterion is based on a single measurement of kidney function (estimated glomerular filtration rate [eGFR] ≤20 ml/min/1.73m2) and does not consider an individual’s risk of progressing to kidney failure.

10 Nov 2025

SGLT2 inhibitors show consistent cardio-renal protection in 70,000 patients

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists' Consortium (SMART-C), led by The George Institute for Global Health.

7 Nov 2025

Finerenone offers hope for kidney protection in patients with type 1 diabetes

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease.

6 Nov 2025

High levels of albumin in the urine linked to increased risk of dementia

A study shows that people with higher levels of the protein albumin in their urine are at increased risk of developing dementia. The study, led by researchers at Karolinska Institutet, is published in the scientific journal Journal of Internal Medicine.

24 Sep 2025

How early-life factors raise lifelong diabetes risks in youth

The surge in diabetes among young people highlights critical gaps in care and the urgent need for comprehensive preventative actions to address this crisis.

19 Jun 2025

Yo-yo dieting found to harm kidney health in type 1 diabetes patients

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other traditional risk factors, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

4 Feb 2025

New GFR formula offers better diagnosis of hyperfiltration in elderly patients

Annual health checkups regularly include urine tests that serve several purposes, including checking for symptoms of kidney disease.

6 Jan 2025

Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

Researchers investigate the clinical efficacy of semaglutide in controlling urine albumin-to-creatinine ratio in overweight patients with chronic kidney disease.

31 Oct 2024

Ozempic effective for patients with chronic kidney damage

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic kidney disease and obesity.

28 Oct 2024

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

13 Sep 2024